Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Voclosporin - Aurinia Pharmaceuticals

Next Previous
X
Search
Drug Profile

Voclosporin - Aurinia Pharmaceuticals

Alternative Names: trans-ISA 247; trans-R 1524; ISA(TX)247; ISA-247; ISAtx 247; ISATx247; LUPKYNIS; Orelvo; R-1524; Voclera

Latest Information Update: 25 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isotechnika
  • Developer Atrium Medical Corporation; Aurinia Pharmaceuticals; Isotechnika; Leiden University Medical Center; Otsuka Pharmaceutical; Paladin Labs
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies; Small molecules; Urologics; Vascular disorder therapies
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lupus nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lupus nephritis
  • Phase II COVID 2019 infections; Focal segmental glomerulosclerosis
  • No development reported Nephrotic syndrome; Renal transplant rejection
  • Discontinued Coronary artery restenosis; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 18 Nov 2024 Updated efficacy data from the phase III AURORA 1 trial in Lupus nephritis released by Aurinia Pharmaceuticals
  • 24 Sep 2024 Registered for Lupus nephritis (Adjunctive treatment) in Japan (PO)
  • 01 Aug 2024 Aurinia Pharmaceuticals expects approval of JNDA for Voclosporin from Japanese Ministry of Health, Labour, and Welfare in 2H of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top